Athira pharma announces initiation of patient dosing in shape, a phase 2 clinical trial of ath-1017 for the treatment of parkinson's disease dementia and dementia with lewy bodies

Bothell, wash., jan. 25, 2022 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in shape, a phase 2 clinical trial of ath-1017 for the treatment of parkinson's disease dementia and dementia with lewy bodies. ath-1017 is a small molecule designed to enhance the activity of hepatocyte growth factor (hgf) and its receptor, met, to impact neurodegeneration and regenerate brain tissue.
ATHA Ratings Summary
ATHA Quant Ranking